Abstract | BACKGROUND: METHODS: A randomized, double-blind, placebo-controlled 12-week trial was performed. Fifty-four subjects with MCI were randomized to an active group ingesting 750 mg of anserine and 250 mg of carnosine per day or a placebo (1:1). Evaluation of cognitive change was conducted utilizing a psychometric test battery. RESULTS: The score improvement in the global Clinical Dementia Rating (gloCDR) was superior in the active group than placebo (p = 0.023). No beneficial effect in the active group was detected in the other psychometric tests including the Mini-Mental State Examination (MMSE), the Wechsler Memory Scale, and the Alzheimer's Disease Assessment Scale (ADAS). When APOE4 positive ( APOE4 (+)) or negative (APOE4 (-)) subjects were separately analyzed, beneficial change in the APOE4 (+) subjects was observed in MMSE (p = 0.025) as well as in gloCDR (p = 0.026). CONCLUSIONS: The present study might suggest that protective effects against cognitive decline in APOE4 (+) MCI subjects exist.
|
Authors | Nobutaka Masuoka, Chitose Yoshimine, Marie Hori, Mieko Tanaka, Takashi Asada, Keiichi Abe, Tatsuhiro Hisatsune |
Journal | Nutrients
(Nutrients)
Vol. 11
Issue 7
(Jul 17 2019)
ISSN: 2072-6643 [Electronic] Switzerland |
PMID | 31319510
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Amyloid beta-Peptides
- Apolipoprotein E4
- Carnosine
- Anserine
|
Topics |
- Aged
- Aged, 80 and over
- Amyloid beta-Peptides
(blood)
- Anserine
(administration & dosage)
- Apolipoprotein E4
(metabolism)
- Carnosine
(administration & dosage)
- Cognition
(drug effects)
- Cognitive Dysfunction
- Dietary Supplements
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
|